12:00 AM
 | 
Feb 09, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Armala pazopanib regulatory update

GSK disclosed in its earnings that in December it submitted an NDA to FDA for Armala pazopanib to treat renal...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >